



Arisha Patel, MD, MBA

Precision Oncologist · Physician-Scientist · Founder and CEO

hello@arishapatelmd.com · arishapatelmd.com

Arisha Patel, MD, MBA is a triple board-certified Oncologist, Hematologist, and Internist and the Founder and CEO of BioNurture and BioSynova. She builds precision oncology for the two parts of cancer care the system was never designed to hold: the years before a diagnosis and the decades after treatment.

Her career has run through every room where cancer care is decided. In the clinic, she practiced as a breast oncologist before broadening across tumor types and the full range of cancer and blood disorders. In the research lab, as an NIH T32-funded physician-scientist, she built machine learning models predicting outcomes in sickle cell disease with a cross-disciplinary team spanning UPMC and Carnegie Mellon, published in the British Journal of Haematology, one of the first physician-led applications of machine learning in clinical outcomes research. In the drug industry, as Senior Medical Director of Personalized Healthcare at Genentech, she served as Medical Director for MyPathway, a tumor-agnostic Phase 2a basket trial whose data supported NCCN Category 2A guideline recommendations and opened evidence-based access to targeted therapy for patients outside traditional approval pathways. In the academic center, she served as Adjunct Clinical Instructor in Oncology and Hematology at Stanford.

She earned her MD at Chicago Medical School at Rosalind Franklin University, completed residency and fellowship at UPMC, and earned her MBA at Carnegie Mellon's Tepper School of Business in Biomedical Entrepreneurship and AI in Healthcare alongside her medical training.

BioNurture is a concierge oncology and hematology practice for cancer prevention, elevated-risk care, survivorship, and complex hematology. BioSynova is the clinical intelligence company behind it, developing the Cancer Resilience Index, a longitudinal measure of cancer risk now in research validation. Together they merge healthcare outcomes research, clinical trial design, and precision oncology into one framework for the whole arc of cancer care.

Her work has been published in The Lancet Oncology, Cancer Discovery, JCO Clinical Cancer Informatics, the British Journal of Haematology, and Cancer, and presented at ASCO (oral late-breaking abstract), AACR, and ASH. She writes The Cancer Resilience Code.

She works with companies, investors, and healthcare organizations as a fractional Chief Medical Officer, advisor, board member, and speaker.